Increasing of renal replacement therapy (RRT) in diabetic patients in Madrid

R. Pérez-García, P. Rodríguez Benítez, E. Verde and F. Valderrábano

Department of Nephrology, Hospital General `Gregorio Marañon', Madrid, Spain

Sir,

To evaluate the outcome of diabetic patients on renal replacement therapy (RRT) we studied all diabetic end-stage renal failure (ESRF) patients treated in our Hospital from 1978 to 1998. Three years ago we reported a similar study up to 1995 [1].

Diabetes mellitus has become the leading cause of ESRF in our health area of Madrid; 30% of all cases of ESRF. The incidence of diabetics starting RRT was 33.3 per million population (pmp) in 1998, while in 1993–1994 diabetes was 15% and 21% pmp, respectively (Table 1Go). The number of diabetics on RRT in 1998 was 135 pmp, with an a overall prevalence of 1054 pmp. The proportion of diabetics on RRT increased from 7.4% in 1986 to 12.7% in 1998. At the same time, the proportion of incident type 2 diabetics/diabetics on RRT increased from 15% in 1987–1988, to 54% in 1993–1994 and to 81% in 1997–1998. Consequently, the mean age of diabetic patients starting RRT increased from 47 years old before 1988, to 58 in 1989–1990 and 63 in 1997–1998 (Table 1Go).


View this table:
[in this window]
[in a new window]
 
Table 1. Epidemiological data of diabetic patients on RRT in health area 1 of Madrid
 
We studied 182 diabetics admitted for renal replacement therapy, 106 males and 76 females. 105 were type 1 diabetics and 77 type 2. Their mean age at starting RRT was 57±12 years (±SD). Haemodialysis (HD) was the first mode of treatment for 128 (70%) diabetics and CAPD for 54. Seventy out of 128 patients on HD were dialysed in the hospital unit, 40% on acetate free biofiltration (AFB) and 58 in two satellite units, which means a higher proportion of diabetics on CAPD and on HD in the hospital unit. Diabetics allocated to CAPD were, on average 5 years younger than patients allocated to HD (P<0.01) and the proportion of type 1 diabetes was higher in CAPD (72%) than in HD (51%), P<0.05.

During the mean follow-up period (51±45 months) 79 patients changed their treatment modality and 45 of them received a kidney allograft. The relative risk of drop-out was higher with CAPD technique when compared to HD. Frequent clinical complications were: ocular (77%), cardiovascular (myocardial infarction 17%), acute cerebrovascular disease (21%), distal angiopathy (35%) and 10% amputation.

By December 1998, 89 patients had died, eight patients were lost for follow-up and 85 patients continued on treatment. Cardiovascular and cerebrovascular diseases (29%) and infections (27%) were the two most frequent causes of death. Death of unknown-causes represented 19% of all deaths. The overall survival (Kaplan Meier) was 92%, 80%, 72%, 61% and 54% at 1, 2, 3, 4 and 5 years, respectively (57 patients completed the last period). Survival was better on HD than on CAPD, but without statistical significance, although there was significant difference in age and in proportion of type 2 diabetes between both groups. Data analysis estimated by Cox proportional hazards regression showed that younger age and kidney transplantation had a positive independent effect on survival, while clinical distal angiopathy had a significant negative effect on survival. Ischaemic cardiopathy did not have an independent effect on survival. This difference with respect to distal angiopathy may be explained by the effective diagnostic and treatment programme for ischaemic cardiopathy at our hospital.

In 1994, the annual incidence of ESRD from diabetes mellitus was 70 patients pmp in the US, compared to 198 patients pmp per year with ESRD overall. These figures represent 35% of all new admissions for RRT for diabetes during that year. In the period 1992–1996 [2] 39.2% of new patients were diabetic. The incidence in Europe remained lower than in the US during the same period, but showed a continuous increase although with great variations between the different European countries [3]: 10.4 diabetics pmp in Lombardia and 52 in lower Neckar, Germany. Our incidence is intermediate between both figures but higher than that of other areas in Spain [4], except for the Canary Islands. There is a relationship between the incidence and the proportion of type 2 diabetes/diabetes admitted for RRT: 48% in Lombardia, 90% in Lower Neckar Germany and 81% in our data [2].

What are the causes of the rising number of ESRF in patients with diabetes and the geographical variations? Firstly, the prevalence of type 2 diabetes in the population is on the increase, partially because of the ageing of society, economic improvement and a sedentary lifestyle [5]; secondly, survival in type 2 diabetic patients has improved continuously in the last decade; thirdly, the growing widespread availability of RRT and acceptance of elderly patients for this therapy has increased. Genetic, ethnic, nutritional aspects and lifestyle may partially explain the different incidences of ESRF in diabetics between the European countries, but all these factors cannot have changed significantly enough in 10 years to explain such a marked increase in differences between bordering geographical areas. Different developments in health care may play an important role in this question. If that is true, the differences in the incidence will become less significant in the next years.

The 5-year survival rate in this group of diabetic patients is 10–20% better than that of other reports [3,4,6,7]. The cause of that result may be due to a higher proportion of diabetic patients with a kidney allograft and a lesser proportion of elderly patients on CAPD; the concept of `integrated RRT' for diabetics is also very important. Diabetics on RRT need to change frequently from one modality of treatment to another, from CAPD to haemodialysis, etc. Early treatment of clinical complications and a preventive policy regarding vascular access complications are also of considerable influence [8]. The characteristics of haemodialysis treatment in our hospital are: high quality dialysate with bicarbonate; 70% of highflux dialysers; 40% AFB in hospital unit; Kt/V higher than 1.2 (Sargent, Gotch) or 1.35 (Daugirdas II); dialysis duration between 3 and 4 h per session and most important, the achievement of good tolerance. AFB allows better control of acid–base metabolism, nutritional status and tolerance than bicarbonate haemodialysis in diabetics [9].

Micro and macroangiopathy remain the major clinical problem in diabetics on RRT, which affect the morbidity and mortality rates of these patients. In our experience distal angiopathy is a significant mortality risk factor. New strategies for the prevention of angiopathy and nephropathy in diabetic patients are necessary.

References

  1. Perez-Garcia R, DallÁnesse C, Jofre R et al. Tratamiento substitutivo de la función renal en diabéticos: diecisiete años de experiencia. Nefrología 1996; 16 [Suppl 3]: 52–58
  2. USRDS. II. Incidence and prevalence of ESRD. Am J Kid Dis 1998; 32 [Suppl 1]: 38–49
  3. Rychlik I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant 1998; 13 [Suppl 8]: 6–10[Free Full Text]
  4. Rodriguez JA, Cleries M, Vela E and renal Registry Committee. Diabetics patients on renal replacement therapy: analysis of Catalonia. Nephrol Dial Transplant 1997; 12: 2501–2509[Abstract]
  5. Ruggenenti P, Remuzzi G. Nephropathy of type-2 diabetes mellitus. J Am Soc Nephrol 1998; 9: 2157–2169[ISI][Medline]
  6. Abaigar P, Acebal A, Anitua SC et al. Grupo de estudio de la Sociedad Nefrologica del Norte. Tratamiento de sustitución en la nefropatia diabetica. Nefrologia 1992; 12: 121–127[ISI]
  7. Renal Data System. USRDS 1996. Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD; 1997
  8. Ridao N, Polo JR, Pérez-García R, Sánchez M, Réngel MA, Gómez Campderá FJ. Accesos vasculares para diálisis en el anciano. Nefrologia 1998; 13 [Suppl 4]: 22–26
  9. Verzetti G, Navino C, Bolzani R, Galli G, Panzetta G. Acetate-free biofiltration versus bicarbonate haemodialysis in the treatment of patients with diabetic nephropathy: a cross-over multicentric study. Nephrol Dial Transplant 1998; 13: 955–961[Abstract]